Objective This study aimed to develop and validate a machine learning–based predictive model for individualized assessment and management of chemotherapy-induced myelosuppression (CIM) in patients with colorectal cancer (CRC). Methods A total of 450 patients with CRC undergoing chemotherapy were retrospectively enrolled in the training cohort, and an additional 150 patients were included for external validation. Feature selection was performed using the Least Absolute Shrinkage and Selection Operator (LASSO) regression. Three machine learning algorithms Logistic Regression (LR), Random Forest (RF), and Extreme Gradient Boosting (XGBoost) were applied to construct predictive models. Model performance was assessed using multiple metrics, including accuracy, area under the receiver operating characteristic curve (AUC), F1 score, sensitivity, and specificity. The SHapley Additive exPlanations (SHAP) method was employed to rank and interpret the importance of predictive features. Results In the training cohort, 52.4% of patients developed CIM. The feature selection process identified 19 significant variables that were incorporated into the predictive models. Both LR and RF demonstrated optimal performance, with an AUC of 0.83 and an accuracy of 0.76 in the training set. In the test set, RF continued to outperform other models, achieving an AUC of 0.77 and an accuracy of 0.71. External validation confirmed the robustness of the RF model, which achieved an AUC of 0.93 (95% CI: 0.89–0.97), an accuracy of 0.89, a sensitivity of 0.86, and a specificity of 0.92. SHAP analysis revealed that the most important predictors included hematological parameters, nutritional risk score (NRS2002), and a history of radiotherapy. Conclusion The RF-based machine learning model demonstrated high accuracy and strong external validation capability for predicting the risk of CIM in CRC patients.
Song et al. (Wed,) studied this question.